Search for European Projects

17 European Projects Found

Searched on 125080 European Projects

 FINISHED 

BIOlogical therapy CYCLEs towards tailored, needs-driven, safer and cost-effective management of Crohn’s disease (BIOCYCLE)

Start date: Apr 1, 2015, End date: Mar 31, 2021,

"The BIOCYCLE Project proposes to test and critically assess the benefits and risks of an innovative regimen for improving the treatment of Crohn’s disease (CD), a chronic immune-mediated inflammatory disease affecting the gastro-intestinal tract of an increasing number of patients. Currently, the combination of anti-TNFα monoclonal antibodies and immunosuppressants used without interruption is th ...
Read Project

 13

 FINISHED 

Translating neuroimaging findings from research into clinical practice (PSYSCAN)

Start date: Feb 1, 2014, End date: Jan 31, 2020,

Abstract 9Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standard ...
Read Project

 24

 FINISHED 

Intra Erythrocyte Dexamethasone in the treatment of Ataxia Telangiectasia (IEDAT)

Start date: Jan 1, 2016, End date: Apr 30, 2019,

The main objective of the project is to provide a treatment of the neurological symptoms of patients with Ataxia Telangiectasia (AT), a rare progressively disabling and life-shortening genetic disease for which no therapy is currently available. To achieve this, a pivotal Phase III study will be conducted, to allow regulatory filing to obtain market authorization in EU and USA by 2019. EryDex is a ...
Read Project

 7

 FINISHED 

Perception and Action in Complex Environments (PACE)

Start date: Apr 1, 2015, End date: Mar 31, 2019,

The PACE research and training programme sits at the interface between basic science, technology and clinics, in order to unveil how humans control and adapt their movements in complex, naturalistic environments. Such a research agenda has major consequences for understanding how these movements are impacted by specific brain insults and how these impairments can be compensated for via new rehabi ...
Read Project

 10

 FINISHED 

Multimedia Authoring and Management using your Eyes and Mind (MAMEM)

Start date: May 1, 2015, End date: Apr 30, 2018,

Loss of the voluntary muscular control while preserving cognitive functions is a common symptom of neuromuscular disorders leading to a variety of functional deficits, including the ability to operate software tools that require the use of conventional interfaces like mouse, key-board, or touch-screens. As a result, the affected individuals are marginalized and unable to keep up with the rest of t ...
Read Project

 8

 FINISHED 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Start date: Mar 1, 2012, End date: Feb 28, 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Read Project

 39

 FINISHED 

Phase I trial in recurrent high-grade glioma: High-dose vorinostat with concurrent hypofractionated radiation therapy (Recurrent glioma tx)

Start date: Jan 1, 2013, End date: Dec 31, 2016,

High-grade gliomas are the most frequent type of primary brain tumor in adults. Despite optimal multi-modality treatment the disease almost always recurs, at which point median survival is less than a year. Vorinostat (suberoylanilide hydroxamic acid) is the first member of a new class of anti-cancer compounds - histone deacetylase (HDAC) inhibitors, that modulate global gene expression. The drug ...
Read Project

 1

 FINISHED 

OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) (OPTiMiSE)

Start date: Feb 1, 2010, End date: Jul 31, 2016,

OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) will focus on two goals: optimising current treatments in Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project wi ...
Read Project

 25

 FINISHED 

Classification and longitudinal follow-up of common melanocytic nevi with in vivo reflectance confocal microscopy (NEVUS CLASSIFICATION)

Start date: Dec 1, 2011, End date: Nov 30, 2015,

Nevi are the strongest risk markers of melanoma. Common nevi are still regarded clinically as a single entity, despite data suggesting that nevi consist of distinct subsets, and a new classification reflecting the diversity of nevi is needed. However, classifications by clinical examination or even by low-resolution imaging techniques have been limited by difficulty to correlate with histopatholog ...
Read Project

 1

 FINISHED 

The potential of human kidney stem/progenitor cells for use in drug discovery and regenerative therapy programmes (NEPHROTOOLS)

Start date: Dec 1, 2011, End date: Nov 30, 2015,

Renal disease is a global public health problem, with the incidence of end stage renal disease (ESRD) rising annually. Current treatment options for ESRD are dialysis or renal transplantation, which have significant drawbacks in terms of increased morbidity and mortality, besides placing an increasing economic burden on society. The development of interventions aimed at preventing ESRD, including ...
Read Project

 11

 FINISHED 

Joint European and South African Research Network in Anxiety Disorders (EUSARNAD)

Start date: Oct 1, 2011, End date: Sep 30, 2015,

The overall aim of our proposal is to build on the strengths of an existing European network for research into causes and maintaining factors in anxiety disorders and to extend these by establishing firmer research collaboration with the University of Cape Town in South Africa.Through establishing this research exchange, we aim to share knowledge and expertise among participating centres, and ensu ...
Read Project

 13

 FINISHED 

Angiogenesis Research to Improve Therapies for Vascular Malformations (CVM THERAPY)

Start date: Mar 15, 2011, End date: Mar 14, 2015,

Congenital Vascular Malformations (CVM) are a group of diseases characterized by an inborn, localized defects of vascular morphogenesis. Occurring mainly on the face or other highly visible part of the body, the presence of CVM can cause emotional and social problems. Moreover, some malformations are painful or even life-endangering. Current treatments do not achieve optimal or long-lasting result ...
Read Project

 1

 FINISHED 

A Modular Nanosystems Platform for Advanced Cancer Management: Nano-vehicles; Tumor Targeting and Penetration Agents; Molecular Imaging, Degradome based Therapy (SAVEME)

Start date: Mar 1, 2011, End date: Feb 28, 2015,

SaveMe project will address current urgent needs for pancreatic cancer diagnosis and treatment by exploiting partners’ expertise and most recent research achievements for the design and development of novel modular nanosystems platform integrating new functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems per diagnostic or th ...
Read Project

 23

 FINISHED 

WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients (WINTHER)

Start date: Mar 1, 2013, End date: Feb 28, 2015,

Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patientsCurrent medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, ...
Read Project

 12

 FINISHED 

The role of Salmonella Pathogenicity Islands in salmonellosis outbreaks and invasive disease (Role of SPIs)

Start date: Feb 1, 2010, End date: Jan 31, 2014,

Non-typhoid Salmonella (NTS) enterica is a major cause of foodborne infections in industrialized countries and a leading cause of hospitalization and death among bacterial foodborne pathogens. The vast majority of the Salmonella virulence factors are encoded within horizontally acquired discrete regions along the chromosome known as Salmonella Pathogenicity Islands (SPIs). SPIs are crucial for Sal ...
Read Project

 1

 FINISHED 

Nanoscopically-guided induction and expansion of regulatory hematopoietic cells to treat autoimmune and inflammatory processes (NanoII)

Start date: Dec 1, 2009, End date: Nov 30, 2013,

We propose a multidisciplinary program, focusing on the development of novel approaches for directing the differentiation, proliferation and tissue-tropism of specific hematopoietic lineages, using micro- and nano-fabricated cell chips. We will use advanced nanofabricated surfaces functionalized with specific biomolecules, and microfluidics cell chips to specify and expend regulatory immune cells ...
Read Project

 10

 FINISHED 

Comprehensive characterization of epigentic reprogramming in cancer (Cancer Epigenetics)

Start date: Mar 1, 2008, End date: Feb 29, 2012,

Epigenetics refers to heritable changes in gene expression patterns, brought about by modifications to DNA and chromatin. Aberrant epigenetic activity was shown to play important roles in the tumorigenic process. Two major epigenetic systems are known: DNA methylation and the histone modification machinery, an important component of which is the Polycomb Repressive Complexes (PRC) system. Recent w ...
Read Project

 1